Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s

CONFERENCE COVERAGE 2025-04-11 Conference Coverage Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, scientists shared their latest findi

PrimeC

THERAPEUTICS NeuroSense Therapeutics Ciprofloxacin and Celecoxib Combination Inflammation Metals Other From November 2019 to January 2021, a one-year, open-label pilot trial in Israel enrolled 16 ALS patients. Participants took 909 mg celecoxib and ciprofloxacin daily

PAPER Nagel MA, Bubak AN

Varicella Zoster Virus Vasculopathy.

J Infect Dis. 2018 Sep 22;218(suppl_2):S107-S112. PubMed.

Zapping the Zoster Virus, Dodging Dementia

RESEARCH NEWS 2025-04-11 Research News Vaccination against shingles may come with a surprising perk. A recent study posits that the vaccine for herpes zoster, also known as shingles, protects against more than a painful, angry rash. According to real-world data, individuals who r

PAPER Mabuchi F, Tang S, Ando D, Yamakita M, Wang J, Kashiwagi K, Yamagata Z, Iijima H, Tsukahara S

The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population.

Mol Vis. 2005 Aug 12;11:609-12. PubMed.

PAPER Shi Y, Liu W, Hu J, Qiu WQ, He X, Gao Y, Zhang X, Fan Z

The Role of Menopause and Its Association with the Apolipoprotein E4 Allele for Age at Diagnosis of Glaucoma in Women.

Ophthalmol Sci. 2025;5(4):100726. Epub 2025 Jan 31 PubMed.

AD/PD™ 2025: Advances in Science & Therapy

CONFERENCE COVERAGE SERIES Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s New Partnership Forms to Harness AI for Alzheimer’s Research AD/PD™ 2025: Advances in Science & Therapy

PAPER Andrieu S, Bateman RJ, Bereczki E, Bose N, Brookes AJ, Doraiswamy PM, Kivipelto M, Kohlhaas S, Kourtis L, Middleton LT, Moore GJ, Petrella JR, Postlethwaite N, Sainz-Fuertes R

Harnessing artificial intelligence to transform Alzheimer's disease research.

Nat Med. 2025 Apr 1; Epub 2025 Apr 1 PubMed.

NUZ-001

THERAPEUTICS N-[(2S)-2-cyano-1-[5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl]-4-(trifluoromethylsulfanyl)benzamide Neurizon Therapeutics S-Monepantel Zolvix® Small Molecule Other A Phase 1 pilot in six cancer patients found 28 days of 5 mg/kg daily monepantel to hav

Takaomi Saido on ALS or Alzheimer’s? Blood Phospho-Tau Could Mean Either

COMMENT Gonzalez-Ortiz devised a new method to quantify brain-derived tau (Gonzalez-Ortiz et al., 2022). If this technology can distinguish between brain- and muscle-derived tau species, it will be possible to determine whether the phospho-tau species detected in

Kristján Holt

The University of Ediburgh
United Kingdom

PAPER Nadh AG, Kunhikrishnan MJ, Ravi V, Ramakrishnan K, Rehman N, Adithya KS, Revikumar A, Sudhakaran PR, Raju R

Convolidine as potent BACE1 inhibitor for Alzheimer's disease; in-silico coupled with in-vitro assessment.

J Comput Aided Mol Des. 2025 Apr 10;39(1):13. PubMed.

PAPER Mohammadi S, Dolatshahi M, Rahmani F, Raji CA

Altered Clearance in Alzheimer's Disease and Cerebral Amyloid Angiopathy.

Neuroimaging Clin N Am. 2025 May;35(2):277-286. Epub 2025 Feb 19 PubMed.

PAPER Cogswell PM, Burkett BJ, Johnson DR, Pillai JJ

Altered Clearance and Amyloid-Related Imaging Abnormalities.

Neuroimaging Clin N Am. 2025 May;35(2):267-275. Epub 2025 Feb 19 PubMed.

PAPER Shan X, Tao W, Li J, Tao W, Li D, Zhou L, Yang X, Dong C, Huang S, Chu X, Zhang C

Corrigendum to "Kai-Xin-San ameliorates Alzheimer's disease-related neuropathology and cognitive impairment in APP/PS1 mice via the mitochondrial autophagy-NLRP3 inflammasome pathway" [J. Ethnopharmacol. 329 118145].

J Ethnopharmacol. 2025 Apr 10;:119769. Epub 2025 Apr 10 PubMed. Corrected paper.